Shares of AbbVie Inc. ABBV inched 0.33% higher to $191.90 Thursday, on what proved to be an all-around great trading session ...

AbbVie Inc. closed $6.44 short of its 52-week high ($199.95), which the company achieved on September 3rd.

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

AbbVie Inc (NYSE:ABBV) released topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in ...

AbbVie has revealed positive data from a post-hoc analysis of Phase III trials of RINVOQ in treating atopic dermatitis (AD).

According to the last reported balance sheet, AbbVie had liabilities of US$41.9b due within 12 months, and liabilities of ...

Abbvie Inc. failed to defeat a proposed class action by a Chicago-area technician who says he and other workers were ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $193.51 which represents a decrease of $-0.32 or -0.17% from the prior close of $193.83. The stock opened at $192.95 and touched a low of $191.

Alvotech is one of two companies known to have initiated a global or multi-country confirmatory patient study for a biosimilar candidate to ...

Vysis, Inc., a leading genomic disease management ... Abbott created the Established Pharmaceuticals Division in 2010. The creation of AbbVie In 2011, Abbott announced it was to separate into ...